{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:15Z","timestamp":1793666775752,"version":"4.5.1"},"reference-count":139,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Samsung Bioepis Co., Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/14712598.2025.2508838","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T12:11:56Z","timestamp":1747829516000},"page":"615-632","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["The \u2018totality of evidence\u2019 and \u2018extrapolation\u2019 of SB17, a ustekinumab biosimilar"],"prefix":"10.1080","volume":"25","author":[{"given":"Jae Hee","family":"Cheon","sequence":"first","affiliation":[{"name":"Yonsei University College of Medicine and Inflammatory Bowel Disease Center","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-6325","authenticated-orcid":false,"given":"Byong","family":"Duk Ye","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital - IRCCS","place":["Milan, Italy"]},{"name":"Humanitas University","place":["Pieve Emanuele, Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rieder","sequence":"additional","affiliation":[{"name":"Hepatology and Nutrition, Digestive Diseases Institute, Cleveland Clinic","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"University of Verona","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojung","family":"Jung","sequence":"additional","affiliation":[{"name":"Samsung Bioepis","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1903"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815"},{"key":"e_1_3_6_5_1","unstructured":"Stelara FDA Approval History. [cited 2024 Jun 19]. Available from: https:\/\/www.drugs.com\/history\/stelara.html"},{"key":"e_1_3_6_6_1","unstructured":"European Medicines Agency. Stelara SmPC. 2023 [cited 2024 Jun 27]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2171248"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0717-1"},{"key":"e_1_3_6_13_1","unstructured":"European Medicines Agency. Biosimilars in the EU - Information guide for healthcare professionals. 2019 [cited 2024 Jun 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"e_1_3_6_14_1","unstructured":"U.S. Food and Drug Administration. Biosimilars review and approval. 2022 [cited 2024 Jun 21]."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.02.019"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00034-7"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz059"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp180138"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303376"},{"key":"e_1_3_6_21_1","unstructured":"Association for Accessible Medicines (AAM). 2024 U.S. Generic & biosimilar medicines savings report. 2024 [cited 2025 Feb 21]. Available from: https:\/\/accessiblemeds.org\/resources\/blog\/2024-savings-report\/"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00395-w"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2350440"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2020.09.006"},{"key":"e_1_3_6_26_1","unstructured":"European Medicines Agency. Pyzchiva: EPAR - Medicine overview. 2024 [cited 2024 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pyzchiva-epar-medicine-overview_en.pdf"},{"key":"e_1_3_6_27_1","unstructured":"European Medicines Agency. Pyzchiva: EPAR - Public assessment report. 2024 [cited 2024 Jun 21]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pyzchiva-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_6_28_1","unstructured":"U.S. Food and Drug Administration. Pyzchiva: highlights of prescribing information. 2024 [cited 2025 Jan 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761373s002 761425s002lbl.pdf"},{"key":"e_1_3_6_29_1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - revision 1. 2015 [cited 2024 Jun 21]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-medicines\/generic-hybrid-applications"},{"key":"e_1_3_6_30_1","article-title":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues","volume":"1","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Revision. 2014 [cited 2024 Jun 20];1. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf","journal-title":"Revision"},{"key":"e_1_3_6_31_1","unstructured":"European Medicines Agency. Uzpruvo: SmPC. 2024 [cited 2024 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/uzpruvo-epar-medicine-overview_en.pdf"},{"key":"e_1_3_6_32_1","unstructured":"United States Food and Drug Administration. Selarsdi: highlights of prescribing information. 2024 [cited 2024 Dec 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761343s002lbl.pdf"},{"key":"e_1_3_6_33_1","unstructured":"European Medicines Agency. Wezlana: SmPC; 2024 [cited 2024 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wezenla-epar-product-information_en.pdf"},{"key":"e_1_3_6_34_1","unstructured":"United States Food and Drug Administration. Wezlana: highlights of prescribing information. 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761285s000 761331s000lbl.pdf"},{"key":"e_1_3_6_35_1","unstructured":"BioFactura and CuraTeQ Sign Exclusive License for BFI-751 - a biosimilar to stelara. 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.biofactura.com\/biofactura-and-curateq-sign-exclusive-license-for-bfi-751-a-biosimilar-to-stelara\/"},{"key":"e_1_3_6_36_1","unstructured":"Celltrion submits marketing application for CT-P43 biosimilar to Janssen\u2019s Stelara\u00ae. (Ustekinumab). 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.lexology.com\/library\/detail.aspx?g=05875d9e-610d-4640-aa43-65b4735d03ab"},{"key":"e_1_3_6_37_1","unstructured":"Celltrion files MAA with EMA for biosimilar to Janssen\u2019s Stelara\u00ae (ustekinumab). 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.pearceip.law\/2023\/05\/26\/celltrion-files-maa-with-ema-for-biosimilar-to-janssens-stelara-ustekinumab\/"},{"key":"e_1_3_6_38_1","unstructured":"EMA accepts MAA for dong-A ST\u2019s ustekinumab biosimilar. 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.bigmoleculewatch.com\/2023\/07\/21\/ema-accepts-maa-for-dong-a-sts-ustekinumab-biosimilar\/"},{"key":"e_1_3_6_39_1","unstructured":"FDA accepts biologics license application for ustekinumab biosimilar DMB-3115. 2024 [cited 2024 Jun 21]. Available from: https:\/\/www.hcplive.com\/view\/fda-accepts-biologics-license-application-for-ustekinumab-biosimilar-dmb-3115"},{"key":"e_1_3_6_40_1","unstructured":"Formycon and fresenius kabi announce file acceptance for FYB202 a biosimilar candidate to stelara\u00ae (ustekinumab) by the U.S. Food and drug administration. 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.formycon.com\/en\/blog\/press-release\/file-acceptance-fyb202\/"},{"key":"e_1_3_6_41_1","unstructured":"Fresenius Kabi and formycon announce EMA submission acceptance of the marketing authorization application for FYB202 an ustekinumab biosimilar Candidate. 2023 [cited 2024 Jun 21]. Available from: https:\/\/www.fresenius-kabi.com\/news\/ustekinumab-biosimilar-ema-submission-acceptance"},{"key":"e_1_3_6_42_1","unstructured":"U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product - guidance for industry. 2015 [cited 2024 Jun 26]. Available from: https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00501-6"},{"key":"e_1_3_6_44_1","unstructured":"European Medicines Agency. Pyzchiva: SmPC. 2024 [cited 2024 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pyzchiva-epar-product-information_en.pdf"},{"key":"e_1_3_6_45_1","unstructured":"U.S. Food and Drug Administration. Clinical pharmacology data to support a demonstration of Biosimilarity to a reference product - guidance for industry. 2016 [cited 2024 Sep 9]. Available from: https:\/\/www.fda.gov\/media\/88622\/download"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.042"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP204492"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.04.045"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.640"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2436607"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1298473"},{"key":"e_1_3_6_52_1","unstructured":"U.S. Food and Drug Administration. Stelara: clinical pharmacology and biopharmaceutics reviews. 2009 [cited 2024 Aug 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125261s000_ClinPharmR.pdf"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202200112"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1090312"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1301"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1211"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00441-7"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1305"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2215426"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2235263"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00630-5"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.110"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1790-3"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0018-5"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14267"},{"issue":"9","key":"e_1_3_6_66_1","first-page":"515","article-title":"Is a biologic produced 15 Years Ago a biosimilar of itself Today?","volume":"9","author":"Mehr SR","year":"2016","unstructured":"Mehr SR, Zimmerman MP. Is a biologic produced 15 Years Ago a biosimilar of itself Today? Am Health Drug Benefits. 2016 Dec;9(9):515\u2013518.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0088-z"},{"key":"e_1_3_6_68_1","unstructured":"U.S. Food and Drug Administration. Stelara: highlights of prescribing information. 2023 [cited 2024 Jul 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125261s158 761044s009lbl.pdf"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-016-7388-9"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2006.06.010"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwp079"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235681"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.11.035"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0218-5"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.5532"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw198"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.07.019"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.011"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S124476"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.10.003"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.08.003"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1086\/511051"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-007-0397-0"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135245"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.311"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_3_6_90_1","unstructured":"European Medicines Agency. Pyzchiva | European Medicines Agency (europa.eu). 2024 [cited 2024 Aug 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pyzchiva"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead177"},{"key":"e_1_3_6_92_1","unstructured":"U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: update - guidance for industry. 2024 [cited 2024 Sep 9]. Available from: https:\/\/www.fda.gov\/media\/124907\/download"},{"key":"e_1_3_6_93_1","unstructured":"FDA approves interchangeable biosimilar for multiple inflammatory diseases. 2023 [cited 2024 Jul 2]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-interchangeable-biosimilar-multiple-inflammatory-diseases"},{"key":"e_1_3_6_94_1","unstructured":"BioSpace. FDA approves PYZCHIVA\u00ae (ustekinumab-ttwe) Samsung Bioepis\u2019 biosimilar to Stelara. 2024 [cited 2024 Sep 9]. Available from: https:\/\/www.biospace.com\/fda-approves-pyzchiva-ustekinumab-ttwe-samsung-bioepis-biosimilar-to-stelara"},{"key":"e_1_3_6_95_1","unstructured":"Alvotech Teva Announce US. FDA approval of SELARSDI\u2122 (ustekinumab-aekn) biosimilar to Stelara\u00ae (ustekinumab). 2024 [cited 2024 Jul 2]. Available from: https:\/\/investors.alvotech.com\/news-releases\/news-release-details\/alvotech-and-teva-announce-us-fda-approval-selarsditm"},{"key":"e_1_3_6_96_1","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU 2023. [cited 2024 Sep 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},{"key":"e_1_3_6_97_1","unstructured":"European Medicines Agency. Pyzchiva: EPAR - All authorised presentations. 2024 [cited 2024 Jul 4]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/all-authorised-presentations\/pyzchiva-epar-all-authorised-presentations_en.pdf"},{"issue":"2","key":"e_1_3_6_98_1","first-page":"116","article-title":"Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients","volume":"102","author":"Johnson C","year":"2018","unstructured":"Johnson C, Zumwalt M, Anderson N. Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients. Cutis. 2018 Aug;102(2):116\u2013118.","journal-title":"Cutis"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1539\/joh.15-0275-RA"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229680700100517"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8673"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.33393\/dti.2021.2342"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.50"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.05.010"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.052688"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.4966.1"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165800"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0265-y"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.038"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1743811"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16926"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08014-z"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314585"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0035"},{"key":"e_1_3_6_121_1","unstructured":"European Medicines Agency. Omvoh: EPAR - All authorised presentations; 2023 [cited 2024 Dec 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/all-authorised-presentations\/omvoh-epar-all-authorised-presentations_en.pdf"},{"key":"e_1_3_6_122_1","unstructured":"European Medicines Agency. Skyrizi: EPAR - Medicine overview. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/skyrizi-epar-medicine-overview_en.pdf"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44050127"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1771182"},{"issue":"6","key":"e_1_3_6_125_1","first-page":"e15481","article-title":"Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: the results based on data from the program \u201ctreatment of moderate and severe forms of plaque psoriasis (B.47","volume":"35","author":"Owczarek W","year":"2022","unstructured":"Owczarek W, Nowakowska A, Walecka I, et al. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: the results based on data from the program \u201ctreatment of moderate and severe forms of plaque psoriasis (B.47. Of The Natl Health Fund In Pol Dermatol Ther. 2022 Jun;35(6):e15481.","journal-title":"Of The Natl Health Fund In Pol Dermatol Ther"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00688-2"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2023.00091"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.11.002"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0671"},{"key":"e_1_3_6_133_1","unstructured":"Jeremias S. Breaking down biosimilar barriers: payer and PBM policies. 2024 [cited 2025 Feb 27]. Available from: https:\/\/www.centerforbiosimilars.com\/view\/breaking-down-biosimilar-barriers-payer-and-pbm-policies"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy150"},{"key":"e_1_3_6_135_1","unstructured":"U.S. Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. 2018 [cited 2024 Jul 8]. Available from: https:\/\/www.fda.gov\/media\/114574\/download"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231173331"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01819-7"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.631"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2021.00173"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01384-0"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2508838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:32:29Z","timestamp":1749814349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2508838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/14712598.2025.2508838"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2508838","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}